Enzyme market in US to reach $ 2.2 bn in 2019
An increasing focus on sustainability by many companies will continue to support enzyme demand in otherwise mature industries, says the new Freedonia report
BS B2B Bureau B2B Connect | Cleveland, USA
Healthcare reform and efforts to combat rising healthcare costs will lead to changes in the medical and pharmaceutical industries that in turn will result in strong gains in enzymes used in the research and biotechnology, in vitro diagnostics, and biocatalyst markets. In more mature industrial markets, efforts to reduce energy and water use will continue to have a positive impact on enzyme demand.
Strong growth in research and biotechnology enzyme demand will result from pharmaceutical companies looking to improve production processes by using biocatalysts and investing in the development of new biopharmaceuticals. “Increased diagnostic testing and genome sequencing in support of a personalised medicine approach, along with greater testing due to more insured people undergoing routine medical care and the generally increased medical care required by an aging population, will further drive enzyme demand,” said Christine O’Keefe, analyst, Freedonia.
Also Read
While the biofuels market was the primary driver of increases in US enzyme demand between 2004 and 2014, growth going forward will be limited, restrained by conflicting government policies, reluctance by vehicle manufacturers to incorporate higher levels of bioethanol into the gasoline supply, and changing consumer driving habits and attitudes toward biofuels.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jun 08 2015 | 8:56 PM IST